HRP20110200T1 - Uporaba tiotropijevih soli u liječenju umjereno postojane astme - Google Patents
Uporaba tiotropijevih soli u liječenju umjereno postojane astme Download PDFInfo
- Publication number
- HRP20110200T1 HRP20110200T1 HR20110200T HRP20110200T HRP20110200T1 HR P20110200 T1 HRP20110200 T1 HR P20110200T1 HR 20110200 T HR20110200 T HR 20110200T HR P20110200 T HRP20110200 T HR P20110200T HR P20110200 T1 HRP20110200 T1 HR P20110200T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- use according
- patients
- persistent asthma
- preparation
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract 12
- 208000006673 asthma Diseases 0.000 title claims abstract 9
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title claims abstract 4
- 230000002085 persistent effect Effects 0.000 title claims 8
- 239000003814 drug Substances 0.000 claims abstract 8
- 150000001450 anions Chemical class 0.000 claims abstract 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910002651 NO3 Inorganic materials 0.000 claims abstract 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims abstract 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000010452 phosphate Substances 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract 2
- 229940095064 tartrate Drugs 0.000 claims abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000024891 symptom Diseases 0.000 claims 4
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 3
- 101150033809 ADRB2 gene Proteins 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 238000011418 maintenance treatment Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Abstract
Uporaba tiotropijevih soli 1 naznačena time, daX- označava anion s pojedinačnim negativnim nabojem, povoljno je da je anion izabran iz skupine koju čine klorid, bromid, jodid, sulfat, fosfat, metansulfonat, nitrat, maleat, acetat, citrat, fumarat, tartarat, oksalat, sukcinat, benzoat i p-toluensulfonat, po izboru u obliku njihovih hidrata i/ili solvata, za izradu lijeka za liječenje astme jačine GINA stupanj 3. Patent sadrži još 7 patentnih zahtjeva.
Claims (8)
1. Uporaba tiotropijevih soli 1
[image]
naznačena time, da
X- označava anion s pojedinačnim negativnim nabojem, povoljno je da je anion izabran iz skupine koju čine klorid, bromid, jodid, sulfat, fosfat, metansulfonat, nitrat, maleat, acetat, citrat, fumarat, tartarat, oksalat, sukcinat, benzoat i p-toluensulfonat, po izboru u obliku njihovih hidrata i/ili solvata, za izradu lijeka za liječenje astme jačine GINA stupanj 3.
2. Uporaba u skladu sa zahtjevom 1, naznačena time, da se koristi za izradu lijeka za liječenje umjereno postojane astme kod pacijenata koji pokazuju dnevno simptome usprkos liječenju s inhalacijskim kortikosteroidima.
3. Uporaba u skladu sa zahtjevom 1 ili 2, naznačena time, da se koristi za izradu lijeka za liječenje umjereno postojane astme kod pacijenata koji pokazuju postojane simptome usprkos liječenju s inhalacijskim beta-2-agonistima kod pacijenata koji nose Arg/Arg genotip na kodonu 16 ADRB2 gena (kromosom 5).
4. Uporaba u skladu s jednim od zahtjeva 1 ili 2, naznačena time, da se koristi za izradu lijeka za liječenje umjereno postojane astme kod pacijenata koji nose Arg/Arg genotip na kodonu 16 ADRB2 gena (kromosom 5) koji pokazuju dnevno simptome usprkos kombiniranom liječenju s inhalacijskim kortikosteroidima i dugo-djelujućim beta-2-agonistima.
5. Uporaba u skladu s jednim od zahtjeva 1 do 4, naznačena time, da se koristi za izradu lijeka za liječenje umjereno postojane astme kada su pacijenti djeca.
6. Uporaba u skladu s jednim od zahtjeva 1 do 5, naznačena time, da se koristi za izradu lijeka za održavajuće liječenje umjereno postojane astme i za prevenciju bronho-opstruktivnih simptoma kod pacijenata koji nisu odgovarajuće kontrolirani pomoću održavajuće kontrolnog liječenja s inhalacijskim kortikosteroidima i dugo-djelujućim beta-2-agonistima.
7. Uporaba u skladu s jednim od zahtjeva 1 do 6, naznačena time, da se koristi za izradu lijeka za treću liniju održavajuće kontrolne terapije za liječenje umjereno postojane astme.
8. Uporaba u skladu s jednim od zahtjeva 1 do 7, naznačena time, da se povoljno po svakoj pojedinačnoj dozi primjenjuje 1-20 μg tiotropija 1'.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100055 | 2006-01-04 | ||
| PCT/EP2006/070135 WO2007077162A1 (en) | 2006-01-04 | 2006-12-22 | Use of tiotropium salts in the treatment of moderate persistent asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110200T1 true HRP20110200T1 (hr) | 2011-04-30 |
Family
ID=35695896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110200T HRP20110200T1 (hr) | 2006-01-04 | 2011-03-18 | Uporaba tiotropijevih soli u liječenju umjereno postojane astme |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20070155773A1 (hr) |
| EP (1) | EP1971332B1 (hr) |
| JP (1) | JP2009525950A (hr) |
| KR (1) | KR20080083060A (hr) |
| CN (1) | CN101355937A (hr) |
| AR (1) | AR059126A1 (hr) |
| AT (1) | ATE500825T1 (hr) |
| AU (1) | AU2006334367B2 (hr) |
| BR (1) | BRPI0620886A2 (hr) |
| CA (1) | CA2634984C (hr) |
| CY (1) | CY1111534T1 (hr) |
| DE (1) | DE602006020620D1 (hr) |
| DK (1) | DK1971332T3 (hr) |
| EA (1) | EA015353B1 (hr) |
| EC (1) | ECSP088588A (hr) |
| ES (1) | ES2362306T3 (hr) |
| HR (1) | HRP20110200T1 (hr) |
| IL (1) | IL192602A (hr) |
| ME (1) | ME01205B (hr) |
| MY (1) | MY146362A (hr) |
| NO (1) | NO20082439L (hr) |
| NZ (1) | NZ570162A (hr) |
| PL (1) | PL1971332T3 (hr) |
| PT (1) | PT1971332E (hr) |
| RS (1) | RS51703B (hr) |
| SI (1) | SI1971332T1 (hr) |
| TW (1) | TW200731976A (hr) |
| UA (1) | UA95271C2 (hr) |
| WO (1) | WO2007077162A1 (hr) |
| ZA (1) | ZA200804436B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009504604A (ja) | 2005-08-06 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重症持続型喘息の治療におけるチオトロピウム塩の使用 |
| WO2015065222A1 (ru) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Фармацевтический ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких, содержащий в качестве активного вещества микронизированный тиотропия бромид, и способ его получения |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| CN110876721A (zh) * | 2018-09-06 | 2020-03-13 | 天津金耀集团有限公司 | 一种含有表面活性剂的噻托溴铵喷雾剂 |
| CN110876720A (zh) * | 2018-09-06 | 2020-03-13 | 天津金耀集团有限公司 | 依地酸盐恰当改变噻托溴铵喷雾剂表面张力的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2425539A (en) * | 1942-10-31 | 1947-08-12 | Aro Equipment Corp | Coupling |
| US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US6156503A (en) * | 1997-03-03 | 2000-12-05 | The Regents Of The University Of California | Diagnosing asthma patients predisposed to adverse β-agonist reactions |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| ES2228965T3 (es) * | 2000-10-12 | 2005-04-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion y su uso para la produccion de un medicamento. |
| US6908928B2 (en) * | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| US6608055B2 (en) * | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| US6919325B2 (en) * | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
| US7951557B2 (en) * | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| BRPI0415636A (pt) * | 2003-11-03 | 2006-12-12 | Boehringer Ingelheim Int | anidrato cristalino com efeito anticolinérgico |
| UY28590A1 (es) * | 2003-11-03 | 2005-06-30 | Boehringer Ingelheim Int | Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen. |
| US7968717B2 (en) * | 2003-11-03 | 2011-06-28 | Boehringer Ingelhein International Gmbh | Crystalline anhydrate with anticholinergic efficacy |
| SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
| US20060269946A1 (en) * | 2005-05-10 | 2006-11-30 | Young Robert P | Methods and compositions for assessment of pulmonary function and disorders |
| US7933722B2 (en) * | 2005-05-20 | 2011-04-26 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
| JP2009504604A (ja) * | 2005-08-06 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重症持続型喘息の治療におけるチオトロピウム塩の使用 |
| US20070167480A1 (en) * | 2005-12-19 | 2007-07-19 | Sicor Inc. | Pure and stable tiotropium bromide |
-
2006
- 2006-12-22 EP EP06830792A patent/EP1971332B1/en not_active Revoked
- 2006-12-22 ES ES06830792T patent/ES2362306T3/es active Active
- 2006-12-22 CN CNA2006800504685A patent/CN101355937A/zh active Pending
- 2006-12-22 ME MEP-2011-62A patent/ME01205B/me unknown
- 2006-12-22 AT AT06830792T patent/ATE500825T1/de active
- 2006-12-22 SI SI200630986T patent/SI1971332T1/sl unknown
- 2006-12-22 JP JP2008548980A patent/JP2009525950A/ja active Pending
- 2006-12-22 DK DK06830792.5T patent/DK1971332T3/da active
- 2006-12-22 RS RS20110147A patent/RS51703B/en unknown
- 2006-12-22 PL PL06830792T patent/PL1971332T3/pl unknown
- 2006-12-22 KR KR1020087019159A patent/KR20080083060A/ko active Search and Examination
- 2006-12-22 UA UAA200809746A patent/UA95271C2/ru unknown
- 2006-12-22 CA CA2634984A patent/CA2634984C/en not_active Expired - Fee Related
- 2006-12-22 NZ NZ570162A patent/NZ570162A/en unknown
- 2006-12-22 DE DE602006020620T patent/DE602006020620D1/de active Active
- 2006-12-22 EA EA200801629A patent/EA015353B1/ru not_active IP Right Cessation
- 2006-12-22 AU AU2006334367A patent/AU2006334367B2/en active Active
- 2006-12-22 BR BRPI0620886-0A patent/BRPI0620886A2/pt not_active Application Discontinuation
- 2006-12-22 WO PCT/EP2006/070135 patent/WO2007077162A1/en active Application Filing
- 2006-12-22 PT PT06830792T patent/PT1971332E/pt unknown
- 2006-12-22 MY MYPI20082435A patent/MY146362A/en unknown
- 2006-12-28 US US11/617,320 patent/US20070155773A1/en not_active Abandoned
-
2007
- 2007-01-03 AR ARP070100019A patent/AR059126A1/es active Pending
- 2007-01-03 TW TW096100183A patent/TW200731976A/zh unknown
-
2008
- 2008-05-22 ZA ZA200804436A patent/ZA200804436B/xx unknown
- 2008-05-28 NO NO20082439A patent/NO20082439L/no not_active Application Discontinuation
- 2008-06-27 EC EC2008008588A patent/ECSP088588A/es unknown
- 2008-07-03 IL IL192602A patent/IL192602A/en active IP Right Grant
-
2011
- 2011-03-18 HR HR20110200T patent/HRP20110200T1/hr unknown
- 2011-06-07 CY CY20111100543T patent/CY1111534T1/el unknown
-
2015
- 2015-04-24 US US14/695,671 patent/US20150224090A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110200T1 (hr) | Uporaba tiotropijevih soli u liječenju umjereno postojane astme | |
| ES2395159T3 (es) | Terapia con pirfenidona e inductores del citocromo P450 | |
| JP2011162556A5 (hr) | ||
| HRP20110232T1 (hr) | Antagonisti muskarinskog acetilkolinskog receptora | |
| JP2012062329A (ja) | 併用化学療法 | |
| JP2018184465A5 (hr) | ||
| RU2010121827A (ru) | Композиции для лечения болезни паркинсона | |
| ES2791710T3 (es) | Nueva forma de administración de racecadotrilo | |
| JP2013209384A5 (hr) | ||
| JP2018035162A5 (hr) | ||
| JP2013501224A5 (hr) | ||
| JP2008503504A5 (hr) | ||
| TW200524639A (en) | Memantine oral dosage forms | |
| CN107847480A (zh) | 呼吸性疾病的治疗 | |
| CN105461694A (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| US20210401851A1 (en) | Par-4 agonists for the treatment of cancer | |
| JP2014512355A5 (hr) | ||
| JP2007505139A5 (hr) | ||
| EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол | |
| JP2012502103A5 (hr) | ||
| CN103263416A (zh) | 一种吡啶胺化合物在制备适于口服给药的治疗肺癌的药物中的应用 | |
| CN105963244A (zh) | 注射用青蒿琥酯制剂及其应用 | |
| JP2007197423A5 (hr) | ||
| CN102319208A (zh) | 一种治疗化放疗所致口腔黏膜炎的悬浮液组合物 | |
| HRP20231131T1 (hr) | Protutumorski farmaceutski pripravci za kombiniranu terapiju |